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Abstract: Background: The microbial colonization of the neonatal gut provides a critical stimulus for
normal maturation and development. This process of early microbiota establishment, known to be
affected by several factors, constitutes an important determinant for later health. Methods: We studied
the establishment of the microbiota in preterm and full-term infants and the impact of perinatal
antibiotics upon this process in premature babies. To this end, 16S rRNA gene sequence-based
microbiota assessment was performed at phylum level and functional inference analyses were
conducted. Moreover, the levels of the main intestinal microbial metabolites, the short-chain fatty
acids (SCFA) acetate, propionate and butyrate, were measured by Gas-Chromatography Flame
ionization/Mass spectrometry detection. Results: Prematurity affects microbiota composition at
phylum level, leading to increases of Proteobacteria and reduction of other intestinal microorganisms.
Perinatal antibiotic use further affected the microbiota of the preterm infant. These changes involved
a concomitant alteration in the levels of intestinal SCFA. Moreover, functional inference analyses
allowed for identifying metabolic pathways potentially affected by prematurity and perinatal
antibiotics use. Conclusion: A deficiency or delay in the establishment of normal microbiota function
seems to be present in preterm infants. Perinatal antibiotic use, such as intrapartum prophylaxis,
affected the early life microbiota establishment in preterm newborns, which may have consequences
for later health.
Keywords: intestinal microbiota; microbiome; preterm; infants; antibiotics
1. Introduction
Increasing knowledge about the important role the intestinal microbiota play in human health
has attracted the attention of researchers to factors that determine its development in the host. During
the last decade the improvement and availability of next-generation DNA sequencing techniques has
allowed for carrying out detailed gut microbiota studies, increasing enormously our understanding of
its composition and activity [1–7]. The microbiota varies along the gastrointestinal tract, corresponding
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with different ecological niches from the mouth to the colon. The upper bowel is sparsely populated,
while the colon is heavily colonized, with levels that may reach 1011–1012 bacteria per gram of
content [8].
The key role of early life events in determining the microbiota establishment process in the
newborn, and their impact on later health, is currently well recognized [9,10]. This early colonization
is essential for adequate infant development, constituting the basis for the later physiological,
immunological, and neurological homeostasis of the individual [11–14].
The process of establishment of the microbiota starts at birth and is driven by the interplay
between genetic factors, mode of delivery, environment, and feeding mode and later diet [15]. Recent
studies have monitored the establishment and development of the microbiota in the first days of infant
life [16,17], increasing our understanding of the step-wise evolution of this process. Fecal metabolome
studies have also been carried out underlining the strong relationship between the development
of the microbiota and that of the metabolic pathways in the infant gut [17]. During the very early
days the infant fecal microbiota seems to rely mainly in the catabolism of proteins with production
of free amino acids and branched chain fatty acids, with high levels of proteobacteria. Then the
infant microbiota turns towards the metabolism of carbohydrates with a concomitant increase in the
production of short-chain fatty acids (SCFA) [17]. This initial intestinal colonization process, in spite of
being a critical moment for microbiota development and modulation, remains poorly understood with
significant gaps in the knowledge about the factors affecting it, perhaps with the exception of the mode
of delivery and feeding patterns [16,18,19]. In spite of the existing gaps, a recent study has started
to take advantage of this knowledge and demonstrated the beneficial effect, in terms of microbiota
modulation, of vaginal microbiota transfer in those cases in which the microbiota establishment process
may be challenged, as is the case in C-section delivered babies [20].
Prematurity is known to affect different systems; these infants are born with an immature immune
system [21], which limits their resistance to infection, thereby increasing their risk of disease. In a
previous work [22] we studied the process of establishment of the intestinal microbiota in very-low
birth-weight (VLBW) preterm infants and compared it with that of healthy full-term, vaginally
delivered, exclusively breast-fed (FTVDBF) neonates by 16S rRNA gene profiling and quantitative
PCR for different microbial groups. The results obtained showed clear differences in the process of
intestinal microbiota development in VLBW preterm infants, which is in good agreement with previous
observations [23–28]. In addition, we found that perinatal antibiotic use, including intrapartum
antimicrobial prophylaxis (IAP), affects the gut microbiota development during the critical first
weeks of life. These results have been further confirmed by more recent studies [29] underlining the
importance of IAP as a factor influencing the microbiota establishment in the newborn.
In the present work, we analyzed the data from our previous study [22] at phylum levels and
further extend our study by conducting a functional inference analysis to determine the potential
impact of prematurity and perinatal antibiotics upon the genes present in the intestinal microbiota.
Moreover, we determined the levels of the main intestinal bacterial metabolites, the fecal SCFA acetate,
propionate and butyrate, and compared them among the infant groups.
2. Results and Discussion
2.1. Establishment of the Intestinal Microbiota in Preterm and Full-Term Infants
The analyses of the bacterial phyla present in fecal samples from VLBW preterm and FTVDBF
babies evidenced clear differences between both groups of infants during the first months of life
(Figure 1). Preterm neonates harbored a significantly higher (p < 0.01) relative proportion of Firmicutes
at two days of age, and of Proteobacteria in the later sampling times (p < 0.01 at 10 and p < 0.001 at
30 days of age), than FTVDBF babies. By contrast, premature infants showed reduced levels (p < 0.05)
of Bacteroidetes at day 2 of life and of this phylum and that of Actinobacteria during the first month,
the differences remaining significant (p < 0.05) for up to three months in the case of the phylum
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Bacteroidetes. In FTVDBF babies Proteobacteria, followed by Firmicutes and Bacteroidetes, dominated
the microbiota at two days of age, while in preterms Firmicutes followed by Actinobacteria and
Proteobacteria were the predominant groups (Figure 1). At 10 days of age in FTVDBF newborns
Proteobacteria and Firmicutes co-dominate with a slight increase in the percentage of sequences from
Bacteroidetes and Actinobacteria, a situation that remained stable with only minor changes during the
rest of the study. However, at the same age (10 days) Proteobacteria had become the clearly dominant
population in VLBW preterm infants, followed by Firmicutes, Actinobacteria, and Bacteroidetes.
This situation remained unchanged during the first month of life, with the levels of Firmicutes and
Actinobacteria increasing later on (at 90 days) (Figure 1).
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Figure 1. Aggregate microbiota (%) at phylum level in fecal samples from full-term, vaginally delivered,
exclusively breast-fed (FTVDBF) vs. preterm infants at the different time poi ts analyzed.
Previous studies reported the impact of prematurity upon the process of development of the
intestinal microbiota in the neonate [25,27,30–33]. Our results on the bacterial phyla present in
the samples, which confirm our previous data, show noticeable differences in the gut microbiota
composition between preterm and FTVDBF babies [22,31].
Despite the high inter-individual variation, and in accordance with the observed alterations
on the fecal microbiota composition, differences in the levels of SCFA between VLBW preterm and
FTVDBF infants were also observed. As expected, acetate was the major SCFA in both groups of
infants, followed by propionate and low levels of butyrate. We found a significantly (p < 0.05) lower
concentration of total fecal SCFA in our low-birthweight preterm infants when compared with the
FTVDBF ones. These differences were evident at the first sampling points but tended to disappear
along the study period (Figure 2). These results are in good agreement with previously reported
data obtained in non-low-birthweight premature babies [25]. The alteration in the SCFA pattern
in premature babies indicates a strong metabolic effect of the observed differences in microbiota
composition, suggesting an important alteration of the intestinal microbiota’s functionalities.
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In this regard, when the results of the functional inference analyses of both groups of infants
(VLB preter and FTVDBF) were co pared, we found differences between the . By collapsing
the data at different KEGG levels we found the KEGG level 1 categories etabolis , Cellular
Processes, Environ ental Information Processing, and Genetic Information Processing to be the
most affected, with most of the pathways at KEGG level 2 also displaying statistically significant
differences (p < 0.05 and q < 0.25) between preterm and FTVDBF infants (Table 1). Metabolism
was the most affected category, with preterm infants showing a significantly (p < 0.05 and q < 0.25)
higher frequency of genes from the pathway “xenobiotics biodegradation and metabolism” along
the whole study period, but without reaching statistically significant differences at 90 days of life.
Similarly, preterm babies displayed significantly higher frequencies of genes from the pathways “lipid
metabolism” at two days of life and a trend toward higher levels at 10 days, “metabolism of other
amino acids”, “metabolism of terpenoids and polyketides”, and “nucleotide metabolism” at two days
of age (Table 1). On the other hand, preterm babies showed lower numbers of genes belonging to other
pathways such as “energy metabolism”, “enzyme families”, “glycan biosynthesis and metabolism”,
“metabolism of cofactors and vitamins”, “biosynthesis of other secondary metabolites”, “carbohydrate
metabolism”, or “amino acid metabolism”.
Regarding the categories Cellular Processes, Genetic Information Processing, and Environmental
Information Processing, preterm infants showed a higher relative frequency (p < 0.05 and q < 0.25) than
FTVDBF infants of inferred genes belonging to the pathways “cell growth and death” and “signaling
molecules and interaction” at two days of age, while the opposite was observed for the later sampling
points (Table 1). A similar behavior was observed for inferred genes belonging to the “translation” and
“replication and repair” pathways. The opposite behavior—lower levels at two days in preterm infants
but higher later on—was observed for the “transcription”, “cell motility”, and “signal transduction”
pathways. Moreover, in general, lower frequencies of inferred genes from the pathways “transport
and catabolism” and “folding, sorting, and degradation” were observed in preterm than in full-term
infants during the study period, the contrary being true for “membrane transport” (Table 1).
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Table 1. Relative frequencies (mean ˘ standard deviation (SD)) at the different time points of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (level 2)
belonging to the categories that showed statistically significant differences between preterm and full-term infants. Asterisk denotes statistically significant differences
(p < 0.05 and q < 0.25) after Fañse Discovery Rate (FDR) correction; ns: Non-statistically significant differences.
KEGG Pathways Infants
Day 2 Day 10 Day 30 Day 90
Mean ˘ SD p(t-Test) q-Value Mean ˘ SD
p
(t-Test) q-Value Mean ˘ SD
p
(t-Test) q-Value Mean ˘ SD
p
(t-Test) q-Value
Metabolism
Amino Acid Metabolism
Preterm 8.68 ˘ 0.58 ns 0.558 8.29 ˘ 0.64 * 0.031 8.35 ˘ 0.48 * 0.053 8.61 ˘ 0.66 ns 0.263Term 8.43 ˘ 1.02 9.06 ˘ 0.78 8.86 ˘ 0.61 9.00 ˘ 0.67
Biosynthesis of Other
Secondary Metabolites
Preterm 0.77 ˘ 0.06 ns 0.776 0.66 ˘ 0.08 * 0.037 0.70 ˘ 0.10 * 0.056 0.75 ˘ 0.11 ns 0.391Term 0.74 ˘ 0.24 0.86 ˘ 0.24 0.85 ˘ 0.19 0.82 ˘ 0.22
Carbohydrate Metabolism Preterm 11.53 ˘ 0.64 ns 0.383 10.99 ˘ 0.77 ns 0.902 10.86 ˘ 0.7 * 0.131 10.88 ˘ 0.60 ns 0.497Term 11.16 ˘ 1.08 11.04 ˘ 0.80 11.31 ˘ 0.73 11.11 ˘ 0.76
Energy Metabolism Preterm 4.93 ˘ 0.19 ns 0.544 4.72 ˘ 0.12 * 0.033 4.75 ˘ 0.13 * 0.029 4.91 ˘ 0.31 * 0.550Term 5.08 ˘ 0.63 5.2 ˘ 0.52 5.13 ˘ 0.42 5.26 ˘ 0.46
Enzyme Families Preterm 2.09 ˘ 0.07 ns 0.809 2.03 ˘ 0.05 * 0.039 2.03 ˘ 0.04 * 0.023 2.09 ˘ 0.07 ns 0.327Term 2.08 ˘ 0.15 2.13 ˘ 0.10 2.13 ˘ 0.09 2.13 ˘ 0.09
Glycan Biosynthesis
and Metabolism
Preterm 1.89 ˘ 0.28
* 0.027
2.25 ˘ 0.38
* 0.112
2.35 ˘ 0.25 ns 0.307 2.22 ˘ 0.31 ns 0.343Term 2.73 ˘ 0.82 2.71 ˘ 0.78 2.60 ˘ 0.67 2.50 ˘ 0.73
Lipid Metabolism Preterm 3.08 ˘ 0.24 * 0.006 2.89 ˘ 0.30 ns 0.493 2.78 ˘ 0.12 ns 0.561 2.85 ˘ 0.17 ns 0.640Term 2.83 ˘ 0.16 2.81 ˘ 0.22 2.82 ˘ 0.19 2.90 ˘ 0.22
Metabolism of Cofactors
and Vitamins
Preterm 3.55 ˘ 0.55
* 0.044
3.80 ˘ 0.19
* 0.032
3.88 ˘ 0.26 ns 0.291 3.89 ˘ 0.13 ns 0.387Term 4.07 ˘ 0.52 4.14 ˘ 0.39 4.02 ˘ 0.34 4.03 ˘ 0.18
Metabolism of Other
Amino Acids
Preterm 1.66 ˘ 0.06
* 0.230
1.68 ˘ 0.08 ns 0.892 1.70 ˘ 0.06 ns 0.367 1.65 ˘ 0.13 ns 0.510Term 1.63 ˘ 0.07 1.69 ˘ 0.13 1.68 ˘ 0.07 1.61 ˘ 0.14
Metabolism of Terpenoids
and Polyketides
Preterm 1.74 ˘ 0.13
* 0.052
1.50 ˘ 0.19 ns 0.620 1.44 ˘ 0.08 * 0.034 1.46 ˘ 0.08 ns 0.295Term 1.57 ˘ 0.20 1.53 ˘ 0.14 1.53 ˘ 0.09 1.52 ˘ 0.12
Nucleotide Metabolism
Preterm 4.27 ˘ 0.52
* 0.125
3.23 ˘ 0.63
* 0.030
3.27 ˘ 0.57
* 0.064
3.40 ˘ 0.46 ns 0.279Term 3.85 ˘ 0.63 3.78 ˘ 0.57 3.70 ˘ 0.51 3.67 ˘ 0.40
Xenobiotics Biodegradation
and Metabolism
Preterm 2.57 ˘ 0.35
* 0.000
2.23 ˘ 0.35
* 0.082
2.18 ˘ 0.28
* 0.036
2.08 ˘ 0.41 ns 0.269Term 1.80 ˘ 0.15 1.84 ˘ 0.35 1.87 ˘ 0.31 1.80 ˘ 0.39
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Table 1. Cont.
KEGG Pathways Infants
Day 2 Day 10 Day 30 Day 90
Mean ˘ SD p(t-Test) q-Value Mean ˘ SD
p
(t-Test) q-Value Mean ˘ SD
p
(t-Test) q-Value Mean ˘ SD
p
(t-Test) q-Value
Cellular Processes
Cell Growth and Death
Preterm 0.50 ˘ 0.09
* 0.064
0.30 ˘ 0.09
* 0.034
0.30 ˘ 0.08
* 0.027
0.35 ˘ 0.10 ns 0.289Term 0.40 ˘ 0.11 0.40 ˘ 0.10 0.40 ˘ 0.08 0.41 ˘ 0.08
Cell Motility Preterm 1.12 ˘ 0.47 * 0.151 2.06 ˘ 1.10 ns 0.496 1.98 ˘ 0.97 * 0.121 1.84 ˘ 0.81 ns 0.930Term 1.85 ˘ 1.31 1.67 ˘ 1.30 1.51 ˘ 0.59 1.78 ˘ 0.91
Transport and Catabolism Preterm 0.20 ˘ 0.03 * 0.200 0.18 ˘ 0.03 * 0.049 0.19 ˘ 0.03 * 0.085 0.20 ˘ 0.06 ns 0.317Term 0.29 ˘ 0.18 0.32 ˘ 0.19 0.29 ˘ 0.17 0.31 ˘ 0.18
Genetic Information Processing
Folding, Sorting
and Degradation
Preterm 2.20 ˘ 0.05
* 0.100
2.18 ˘ 0.14
* 0.120
2.19 ˘ 0.10
* 0.112
2.20 ˘ 0.11 ns 0.749Term 2.40 ˘ 0.28 2.34 ˘ 0.28 2.31 ˘ 0.20 2.32 ˘ 0.14
Replication and Repair Preterm 8.76 ˘ 1.06 * 0.126 6.52 ˘ 1.21 * 0.046 6.50 ˘ 0.98 * 0.035 7.00 ˘ 1.14 ns 0.360Term 7.91 ˘ 1.29 7.88 ˘ 1.30 7.60 ˘ 1.07 7.76 ˘ 0.99
Transcription Preterm 2.70 ˘ 0.19 ns 0.839 3.02 ˘ 0.18 * 0.029 3.00 ˘ 0.19 * 0.191 3.05 ˘ 0.20 ns 0.261Term 2.72 ˘ 0.29 2.73 ˘ 0.31 2.86 ˘ 0.27 2.90 ˘ 0.26
Translation
Preterm 5.70 ˘ 0.82
* 0.053
3.93 ˘ 0.99
* 0.039
3.93 ˘ 0.82
* 0.045
4.19 ˘ 0.73 ns 0.266Term 4.74 ˘ 1.08 4.81 ˘ 0.99 4.68 ˘ 0.80 4.57 ˘ 0.58
Environmental Information Processing
Membrane Transport Preterm 15.15 ˘ 1.01 ns 0.345 16.86 ˘ 1.57 * 0.048 16.93 ˘ 1.31 * 0.075 16.54 ˘ 1.59 ns 0.292Term 13.91 ˘ 3.38 14.05 ˘ 3.71 14.75 ˘ 3.11 14.53 ˘ 2.68
Signal Transduction Preterm 1.56 ˘ 0.43 * 0.105 2.50 ˘ 0.49 * 0.066 2.44 ˘ 0.47 * 0.009 2.23 ˘ 0.47 ns 0.283Term 2.05 ˘ 0.71 1.89 ˘ 0.58 1.96 ˘ 0.31 1.93 ˘ 0.49
Signaling Molecules
and Interaction
Preterm 0.27 ˘ 0.07
* 0.147
0.16 ˘ 0.08
* 0.071
0.15 ˘ 0.06
* 0.039
0.17 ˘ 0.05 ns 0.353Term 0.22 ˘ 0.08 0.22 ˘ 0.08 0.21 ˘ 0.06 0.20 ˘ 0.07
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The functional inference analysis carried out suggests an increasing ability of the preterm
infant microbiota to metabolize xenobiotics and a trend toward increased presence of genes related
with cell motility, likely related to the dominance of Proteobacteria in this infant group. Moreover,
a concomitant reduction in the presence of common intestinal microbiota metabolic activities such
as glycan metabolism, or metabolism of vitamins, was observed in VLBW preterm infants when
compared with FTVDBF babies, suggesting a reduced presence of genes related to the functions of the
normal microbiota. In general, as was observed for the microbial composition data, the differences
tended to be reduced over time, in most cases having disappeared by the age of 90 days (Table 1).
A good correlation between total metagenomics and functional inference from 16S rDNA gene profiling
has been previously reported [34], underlining the interest of performing functional inference analyses
when such data are available. It is important to underline that at the end of the study none of the
preterm infants had been exclusively breast-fed or formula-fed and the exposure to breastmilk was
highly variable, as is often the case among preterm babies, while our control group included only
exclusively breast-fed babies. Therefore, the potential impact of the different feeding habits cannot be
overruled as a factor explaining the differences observed between both groups of infants.
In accordance with previous studies [22,25,31], our results suggest a deficiency or delay in the
establishment of a normal microbiota function in the preterm infant gut. Although this deficiency
seems to have been mostly overcome by the age of three months, given the important role of the early
days of life for the maturation of the immune system [21], it could be hypothesized that this alteration
in the early colonization may pose a risk for later health.
2.2. Effect of Perinatal Antibiotics on Microbiota Development in Preterm Infants
In this study we compared four groups of VLBW preterm infants established on the basis of
the administration of antibiotics to the mother (Intrapartum antimicrobial prophylaxis, IAP), to the
infant itself, to both mother and infant, or to none of them (no antibiotic-exposed infants). The results
obtained confirmed, at a high taxonomic level, the previously reported effect of perinatal antibiotics
(including IAP) upon the preterm newborn microbiota [22]. Now the comparison of the 16S rRNA
profiling data at phylum level, among the different antibiotic exposure groups, allowed us to identify
antibiotic-related effects upon the microbiota composition. Interestingly, these effects were not so
apparent in the first days of life, when no statistically significant differences on the bacterial phyla were
observed among the four preterm infant groups (data not shown), as after 30 days when statistically
significant differences were found for Actinobacteria (p < 0.05), Firmicutes (p < 0.01), and Proteobacteria
(p < 0.01) (Figure 3). The relative frequency of the first phylum was significantly higher in antibiotic-free
preterm infants than in the groups where either the mother or the mother and the infant received
antibiotics (p < 0.01 and p < 0.05, respectively). The phylum Firmicutes showed significantly higher
levels in antibiotic-free babies with respect to the two infant groups where mothers received antibiotics
(p < 0.01 in both cases). Interestingly, this phylum was also found to be higher (p < 0.05) in the
antibiotic-receiving preterm babies whose mothers did not receive IAP than in the antibiotic-free
preterm babies whose mothers were administered antibiotics. The opposite behavior to that found for
Firmicutes was observed for the phylum Proteobacteria, whose levels were lower in antibiotic-free
newborns than in those cases in which either the mother (p < 0.05) or the mother and the infant
(p < 0.01) received antibiotics. Moreover, higher Proteobacteria levels (p < 0.05) were found in infants
whose mothers received IAP than in the group in which the infants but not the mothers received the
antibiotics (Figure 3).
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Our results support and extend previous data indicating an effect of perinatal exposure to
antibiotics on the establishing microbiota. Increases in family Enterobacteriaceae (microorganisms
belonging to the phylum Proteobacteria) following antibiotic exposure in neonates have been
repeatedly observed [22,29,35–37]. Although some authors did not find any effect of maternal
antibiotics use during pregnancy on the microbiota development in full-term infants [38], other studies
did [36]. Moreover, in the specific case of IAP, microbiota alterations such as a reduction in the levels of
the family Bacteroidaceae have been observed in both preterm and full-term infants [22,29,39]. Notably,
the observed effect of antibiotics was more pronounced when the antibiotics were administered to
the mother during delivery (IAP) that when the infant itself received them. Moreover, it was also
interesting to note that this alteration on the microbiota development process was not so evident
during the first days of life as at the end of the first month, having almost disappeared by the age of
three months.
In accordance with the microbial data, the concentration of SCFA was also found to be affected,
especially by the IAP administration to the mothers. The high inter-individual variability on SCFA
levels is likely to have prevented the detection of any statistically significant difference among the four
groups of infants. Nevertheless, at 30 days of age infants not exposed to antibiotics at all, or those who
received them but whose mothers did not, showed a trend towards higher levels of acetic (p = 0.075)
and total (p = 0.060) SCFA than the newborns whose mothers received IAP (Table S1).
The results of the functional inference analyses showed differences among the four different
antibiotic exposure groups. In accordance to the microbiota composition data, the age of 30 days was
the time at which statistically significant differences (p < 0.05 and q < 0.25) among the groups were
observed for more functional pathways (Figure 4). The categories Cellular Processes, Metabolism,
Environmental Information Processing, and Genetic Information Processing, were the most affected.
Interestingly, the administration of IAP to the mothers was the most influential factor. The relative
frequency of inferred genes belonging to the pathways “cell growth and death,” “biosynthesis of other
secondary metabolites,” “nucleotide metabolism,” “signaling molecules and interaction,” “replication
and repair,” and “translation” were significantly higher (p < 0.05 and q < 0.25) in the antibiotic-free
babies group with respect to the two groups of babies whose mothers received IAP. Interestingly,
no differences were evident for the abovementioned pathways between the groups of antibiotics-free
babies and the antibiotic-receiving preterm newborns whose mothers did not receive IAP. The opposite
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behavior was observed for the relative frequency of inferred genes belonging to “signal transduction”
(Figure 4), for which higher levels were observed in the infant groups whose mothers received IAP
than in babies not exposed to antibiotics. The functional inference analyses carried out suggest
pathways potentially affected by the use of perinatal antibiotics, mainly of IAP administration to the
pregnant woman.
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These results indicate an effect of perinatal antibiotics, mainly of IAP, on early life microbiota,
which may involve a lasting effect on the individual physiology [13]. The use of antibiotics
may influence microbiota-host crosstalk during the neonatal period, which may have profound
consequences for later health [15]. Actually, perinatal antibiotics exposure has been reported to
increase the risk of later disease such as asthma [40,41]. Given that the estimated use of IAP is over 30%
of total deliveries [42], greater attention should be paid to its potential impact upon the gut microbiota.
This impact should be considered as a factor in the decision on whether or not to administer IAP.
In general, intrapartum prophylaxis is recommended in the case of premature rupture of membranes
and, in some countries in which a screening protocol is established, when vaginal group B streptococci
colonization is observed [43,44]. However, there are other cases in which antibiotics are administered
without a clear benefit [45,46] and in which the use of IAP would be arguable, especially since we are
starting to understand their impact on the early microbiota development and the importance of this
process for later health [7,9,47]. It would be advisable to develop strategies, such as the concomitant
administration of probiotics, aimed at limiting the impact of IAP in the establishing microbiota in those
cases in which IAP is required.
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3. Materials and Methods
3.1. Volunteers and Samples
Thirteen Caucasian FTVDBF infants and 27 Caucasian very low birthweight (VLBW) preterm
infants from a previous work [22] were included in this study. Fourteen of the preterm infants’
mothers received intrapartum antimicrobial prophylaxis (IAP) (penicillin, ampicillin, or ampicillin
plus erythromycin). Twelve infants received antibiotics already during the first week of life, while five
additional infants started antibiotic treatment during the second week. Only five out of the
27 mother/premature infant pairs were not exposed to antibiotics, either intrapartum or postnatally,
and in nine of the pairs the mother received IAP and the infant postnatal antibiotics. Fecal samples
were collected at the hospital between 24 and 48 h of life and at 10, 30, and 90 days of age, immediately
frozen at ´20 ˝C and processed as described by Arboleya and co-workers [22].
3.2. Intestinal Microbiota Analyses
The data from the abovementioned previous study [22], deposited at the National Center for
Biotechnology Information (ShortRead Archive BioProject ID PRJNA230470), were now used to assess
microbial composition at high phylogenetic (phylum) level. These data were obtained from sequencing
of amplicons covering the V3 region generated with optimized primers [48]. UCLUST software and
the Ribosomal Database Project were used for phylogenetic assignations.
3.3. Determination of SCFA in Feces
The analysis of short chain fatty acids (SCFA) was carried out in a chromatographic system
composed of two 6890N GC (Agilent Technologies Inc., Palo Alto, CA, USA) connected to a FID and a
MS 5973N detector as described previously [25].
3.4. Functional Inference Analysis
The functionality of the different metagenomes was predicted using the software PICRUSt 1.0.0
(http://picrust.github.com) [49]. In short, this software allows the prediction of functional KEGG
pathways abundances from the 16S rDNA reads. Firstly, a collection of closed reference OTUs was
obtained from the filtered reads using QIIME v1.7.0 [50] by querying the data against the IMG/GG
reference collection (version 13.5, May 2013, http://greengenes.secondgenome.com). Reverse strand
matching was enabled during the query and OTUs were picked at a 97% identity. A BIOM-formatted
table [51] was obtained with the pick_closed_reference_otus.py script. This table, containing the
relative abundances of the different reference OTUs in all the metagenomes, was normalized by the
predicted 16S rDNA copy number with the script normalize_by_copy_number.py. Final functional
predictions, inferred from the metagenomes, were created with the script predict_metagenomes.py.
When necessary, tab-delimited tables were obtained with the script convert_biom.py.
Predicted metagenomic contents were collapsed at two hierarchical KEGG pathway levels (levels 1
and 2) (http://www.genome.jp/kegg/pathway.html) with the categorize_by_function.py script. Each
of these tables was analyzed statistically in STAMP v2.0.0 [52]. Data of the KEGG pathway distributions,
at different hierarchical levels, were plotted with the script summarize_taxa_through_plots.py.
3.5. Statistical Analyses
In the functional inference analyses, the association of KEGG pathways at the different hierarchical
levels with the different grouping variables was identified by the two-sided Welch’s test for the analysis
of preterm and full-term grouping variables; Kruskal–Wallis was used for the analysis of the four
antibiotics grouping variables; and White´s non parametric t-test was used on every pairwise antibiotic
group comparison. The correction FDR [53] was finally applied in all cases and significant differences
in KEGG pathways between infant groups were only considered below a p-value of 0.05 and a q-value
Int. J. Mol. Sci. 2016, 17, 649 11 of 14
below 0.25 [34]. With regard to the microbiota composition and SCFA results were analyzed using
SPSS software (SPSS Inc., Chicago, IL, USA). The differences among infant groups were analyzed using
the non-parametric Kruskal–Wallis test or, in the case of pairwise comparison, the Mann–Whitney
U-test. Statistical significance was accepted at p < 0.05.
4. Conclusions
Our results indicate a delay in the establishment of the normal microbiota function in preterm
infants. Moreover, these early microbiota alterations are further affected by the use of perinatal
antibiotic, such as intrapartum prophylaxis, in these infants. This alteration in the early microbiota
establishment may have profound consequences for later health. Therefore, it would be advisable
to develop strategies aimed at limiting the impact of prematurity and antibiotics use upon the
establishing microbiota.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/5/649/s1.
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